- This article was considered for deletion at Wikipedia on December 24 2013. This is a backup of Wikipedia:Opexa_Therapeutics. All of its AfDs can be found at Wikipedia:Special:PrefixIndex/Wikipedia:Articles_for_deletion/Opexa_Therapeutics, the first at Wikipedia:Wikipedia:Articles_for_deletion/Opexa_Therapeutics.
Opexa Therapeutics Template:Nasdaq, formerly known as PharmaFrontiers, is a U.S. biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies.
Founded in 2003, the company was originally known as PharmaFrontiers Corp. In October 2004 PharmaFrontiers acquired the privately held company Opexa Pharmaceuticals Inc. In June 2006 the company changed its name to Opexa Therapeutics, Inc.
Research areas and products
Key products and research include:
- Tcelna, previously known as Tovaxin: A proposed T cell therapeutic vaccine for multiple sclerosis, which was granted Fast Track status by the U.S. Food and Drug Administration. In January 2011 the FDA approved the product for Phase 3 clinical trials.
- Heart: early development-stage stem cell therapy (currently in standby)
- Diabetes: early development-stage stem cell therapy (currently in standby)
- "PharmaFrontiers to acquire Opexa". Houston Business Journal. October 8, 2004. http://www.bizjournals.com/houston/stories/2004/10/04/daily45.html. Retrieved 18 August 2012.
- "PharmaFrontiers becomes Opexa Therapeutics, executes stock split". Houston Business Journal. June 19, 2006. http://www.bizjournals.com/houston/stories/2006/06/19/daily3.html. Retrieved 18 August 2012.
- "Opexa sells stem cell tech to Novartis; shares zoom". Reuters. August 7, 2009. http://www.reuters.com/article/2009/08/07/opexa-novartis-idUSBNG19042920090807. Retrieved 18 August 2012.
- "Opexa Therapeutics Announces Tcelna(TM) as New Brand Name for MS Therapy". MarketWatch (Wall Street Journal). May 21, 2012. http://www.marketwatch.com/story/opexa-therapeutics-announces-tcelnatm-as-new-brand-name-for-ms-therapy-2012-05-21. Retrieved 18 August 2012.
- "MS vaccine testing to start in US". BBC News. March 8, 2006. http://news.bbc.co.uk/2/hi/health/4787430.stm. Retrieved 18 August 2012.
- "Opexa drug breakthrough gives firm big-league shot". Houston Business Journal. January 14, 2011. http://www.bizjournals.com/houston/print-edition/2011/01/14/opexa-drug-breakthrough-gives-firm.html. Retrieved 18 August 2012.